Academic History
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, is a Clinical Associate Professor in the Department of Medicine at The University of Hong Kong, Pok Fu Lam, Hong Kong.
Prof. Gill graduated from the University of Hong Kong and went on to join the Department of Medicine at Queen Mary Hospital, Pok Fu Lam, Hong Kong. He then became a Clinical Assistant Professor at the University of Hong Kong and completed his training in Haematology and Haematological Oncology and Advanced Internal Medicine. He has also completed his doctorate degree on the genomics of myeloproliferative neoplasms (MPNs).
Prof. Gill is the service lead for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MPNs at Queen Mary Hospital, and has published extensively in top peer-reviewed journals. His research has focused on the groundbreaking use of oral arsenic trioxide for acute promyelocytic leukemia (APL), achieving remarkable complete remission rates and long-term survival without stem cell transplantation. Prof. Gill also leads studies on the genomics of clonal hematopoiesis, MDS, and MPN, and directs key regional research on myeloid malignancies through the Asian Myeloid Working Group.
Speaking on novel therapeutics and the molecular pathogenesis in MPNs, MDS, and APL
Prof. Gill shares novel treatment approaches, including LSD1 inhibition in MPNs and the AAA regimen in APL. He focuses on chemotherapy-free treatment and discusses the molecular pathogenesis of these diseases.
